

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/642,468	08/15/2003	Zhuyin Li	USAV2002/0098USNP	3125	
5487	7590 12/05/2005		EXAMINER		
ROSS J. O	EHLER PHARMACEUTICALS IN	MEAH, MOHAMMAD Y			
ROUTE 202			ART UNIT	PAPER NUMBER	
MAIL CODE: D303A			1652		
BRIDGEWATER, NJ 08807			DATE MAILED: 12/05/2005		

Please find below and/or attached an Office communication concerning this application or proceeding.

			1 2 2 2 2				
Office Action Summary		Application No.	Applicant(s)	;			
		10/642,468	LI ET AL.				
		Examiner	Art Unit				
		Mohammad Meah	1652				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status							
1)	Responsive to communication(s) filed on						
	This action is <b>FINAL</b> . 2b)⊠ This action is non-final.						
3)	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims							
4)  Claim(s) 1-28 is/are pending in the application.  4a) Of the above claim(s) is/are withdrawn from consideration.  5)  Claim(s) is/are allowed.  6)  Claim(s) is/are rejected.  7)  Claim(s) is/are objected to.  8)  Claim(s) 1-28 are subject to restriction and/or election requirement.							
Application Papers							
	The specification is objected to by the Examine The drawing(s) filed on is/are: a) acceptable as a continuous distance and acceptable as a continuous distance are a continuous distance.		by the Examiner.				
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority under 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some * c) None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.							
2) Not	ent(s)  cice of References Cited (PTO-892)  cice of Draftsperson's Patent Drawing Review (PTO-948)  commation Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  coer No(s)/Mail Date	Paper No	Summary (PTO-413) (s)/Mail Date Informal Patent Application (PTO-152) 				

Application/Control Number: 10/642,468

Art Unit: 1652

## **DETAILED ACTION**

The claims 1-28 are pending in the instant office action.

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

Group II. Claims 1-3, 6-8, 9-12, 16-21 and 27 drawn to screening compound or agent that decrease activities of prostaglandin synthase comprising SEQ ID NO: 2, classified in class 435, subclass 7.72.

Group II. Claims 1, 4-5, 6-8, 13-15, 16, 22-26, 28, drawn to screening compound or agent that decrease activities of prostaglandin synthase comprising SEQ ID NO: 4, classified in class 435, subclass 7.72.

The inventions are distinct, each from the other because of the following reasons:

Inventions in group II and I are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions, inventions of group I and II are method steps involving two different prostaglandin synthases (with distinct amino acid sequence with different structures and functions) and produce different outcomes.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement is traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mohammad Meah whose telephone number is 571-272-1261. The examiner can normally be reached on 8:30-5PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapu Achutamurthy can be reached on 571-272-0928. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Mohammad Younus Meah, PhD

Examiner, Art Unit 1652

Recombinant Enzymes, 3C31 Remsen Bld 400 Dulany Street, Alexandria, VA 22314

Telephone: 517-272-1261

REBECCA E. PROUTE PRIMARY EXAMINER GROUP 1800